Irit Gliko-Kabir
Technik-/Wissenschafts-/F&E-Leiter bei BIOLINERX LTD.
Aktive Positionen von Irit Gliko-Kabir
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOLINERX LTD. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2017 | - |
Karriereverlauf von Irit Gliko-Kabir
Ehemalige bekannte Positionen von Irit Gliko-Kabir
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2014 | - |
Ausbildung von Irit Gliko-Kabir
The Hebrew University of Jerusalem | Doctorate Degree |
Statistik
International
Israel | 4 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Private Unternehmen | 1 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Börse
- Insiders
- Irit Gliko-Kabir
- Erfahrung